EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Basics and practicing guidelines on phenobarbital attributes and effects

Nayab Tahir

Forensic Insights and Health Sciences Bulletin · 2023

DOI: 10.56770/fi20231122 ↗
AbstractBibliografische Angaben

Abstract

Phenobarbital has been used for many years as an anticonvulsant and sedative-hypnotic medication to treat a variety of medical disorders. Malonic acid and diethyl malonate are the main beginning ingredients used in the chemical processes that lead to the creation of phenobarbital. Peak plasma concentrations of phenobarbital are obtained within 2 to 6 hours of oral dosing and are well absorbed. Microsomal enzymes in the liver play a major role in the hepatic metabolism of phenobarbital. The primary metabolic pathway is hydroxylation, which is mostly carried out by the cytochrome P450 enzymes CYP2C9 and CYP2C19. Adults’ elimination half-lives range from 53 to 140 hours, which is a very broad range. Its primary mechanism of action is boosting the inhibitory effects of the central nervous system neurotransmitter gamma-amino butyric acid (GABA). Phenobarbital concentration in blood plasma is measured using a laboratory procedure called plasma level determination of phenobarbital. It is concluded for specific advice and direction on how to use and manage phenobarbital, one must speak with a healthcare practitioner. They have access to medical history and can offer the best advice based on particular requirements.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →